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 Abstract 
  Background:   Patients with type 2 diabetes mellitus and advanced kidney disease are usually 
treated with insulin. However, the prolonged pharmacokinetic insulin profile in patients with 
delayed renal insulin elimination impairs a successful therapy. Due to its hepatic metabolism, 
pioglitazone is a potential candidate for additional administration. The aim of this study was to 
investigate the effect of pioglitazone versus placebo on total daily insulin requirements and 
several pleiotropic factors in type 2 diabetes patients requiring hemodialysis.  Methods:  The ef-
fect of pioglitazone (30 mg) versus placebo was explored in this prospective, randomized, dou-
ble-blind parallel multicenter phase II study analyzing data from 36 patients with type 2 diabe-
tes mellitus currently under hemodialysis (25 male, 11 female, aged 69.2   8   7.9 years, baseline 
HbA1c 7.6   8   0.9%). The most important efficacy parameters collected before dialysis and after 
an overnight fast at baseline and after 6 months were: total daily insulin dose, HbA1c, fasting 
blood glucose, adiponectin, HDL, LDL, triglycerides, NT-proBNP, and ultrafiltrate volume.   Re-
sults:   Application of pioglitazone resulted in a significant decrease of the daily insulin dose by 
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35% versus baseline (placebo: –10%, n.s.), improvement in HbA1c (–0.60   8   0.87%, p = 0.015; 
placebo: 0.21   8   1.1%, n.s.) and adiponectin (7.33   8   4.80 mg/l, p   !   0.001; placebo: –1.37   8   2.56 
mg/l, n.s.). Slight improvements or no changes were seen with fasting glucose, triglycerides, 
HDL, LDL and NT-proBNP. There was no indication of increased hypoglycemia risk and volume 
overload by the addition of pioglitazone.   Conclusions:   Addition of pioglitazone to insulin in 
patients with late-stage kidney failure requiring hemodialysis is a well-tolerated treatment op-
tion that improves glycemic control with simultaneous insulin-sparing potential. 
  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
  Both type 1 and type 2 diabetes mellitus play a major role in the development of kidney 
failure and end stage renal disease (ESRD)   [1]  . The development and progression of diabetic 
nephropathy as well as any other diabetic end-organ damage can be avoided or delayed by a 
sufficient glycemic control defined by international guideline recommendations. Several an-
tidiabetic drugs are currently used for this purpose   [2, 3]  . However, once renal failure has 
progressed to ESRD with the need for hemodialysis, most common oral antidiabetic drugs, 
including metformin, sulfonylurea drugs, GLP1 analogs, and DPPIV inhibitors are contra-
indicated   [4]  . Therefore, hemodialysis patients are currently treated with insulin or insulin 
analogs to control their blood sugar levels. The reduced glomerular filtration rate in renal 
failure that leads to accumulation of most of the oral drugs   [5]   is also responsible for a pro-
longed pharmacokinetic profile of insulin  [6]  so that the insulin dose and the scheduling will 
have to be adapted.
  Besides the negative impact of inadequate glycemic control as a significant cardiovascular 
risk factor, the impaired kidney function results in increased oxidative stress and correspond-
ingly increased cardiovascular risk, especially in patients requiring hemodialysis   [7]  . Several 
potential mechanisms may explain this increased cardiovascular risk. A frequent finding is 
coexistence of several other independent cardiovascular risk factors including dyslipidemia, 
hypertension, and smoking   [8, 9]  . In addition, impaired kidney function is associated with el-
evated markers of inflammation and other putative risk factors for cardiovascular events   [10, 
11]  . Therefore, a therapeutic strategy aiming at a sufficient glycemic control and reduced oxi-
dative stress at the same time seems to be a reasonable approach to reduce the risk of short- and 
long-term consequences, especially the cardiovascular mortality of such patients.
  In general, only drugs that are primarily metabolized and eliminated via the hepatic route 
are suitable in ESRD under hemodialysis. This is the case for the PPAR-   agonist pioglitazone 
(PIO), which is therefore approved for use in chronic renal failure patients   [12]  . Next to its 
hypoglycemic action through reduction of peripheral insulin resistance, PIO has been dem-
onstrated to possess a variety of pleiotropic effects reducing cardiovascular risk, including 
improvement of hypertension, dyslipidemia, chronic systemic inflammation, platelet func-
tion, lipid tissue composition, and atherosclerosis  [13–15] . Furthermore, in the outcome study 
PROactive, PIO significantly reduced cardiovascular endpoints   [16–18]  . In a subanalysis of 
the PROactive study, Schneider et al.   [19]   showed that especially patients with more severe 
degrees of kidney failure, as assessed by glomerular filtration rate, may benefit from treatment 
with PIO.
    The purpose of this study was to investigate the influence of PIO added to insulin ther-
apy on total insulin requirements and the overall risk profile in patients with ESRD under-
going hemodialysis.106
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  Subjects  and  Methods 
 This prospective, randomized, parallel, double-blind, placebo (PLA)-controlled multi-
center phase II trial was approved by the responsible local ethics committees and carried 
out in accordance with the Helsinki Declaration of 1975 between 2008 and 2010. The study 
population consisted of inadequately controlled patients with type 2 diabetes requiring 
dialysis for ESRD. The patients were cared for in 12 centers in Germany. Inclusion criteria 
were type 2 diabetes mellitus, patient on insulin treatment for at least 3 months, age 30–80 
years, HbA1c   6  6.0% and   !  10%, patient on hemodialysis with or without residual excre-
tion, and insulin dose   1  20 IU/day. Exclusion criteria were amongst others history of type 
1 diabetes, acute infections, history of hypersensitivity to the study drugs or to drugs with 
similar chemical structures, history of severe or multiple allergies, progressive fatal disease 
other than kidney failure, history of significant cardiovascular (e.g., CHF NYHA stage 
III–IV), respiratory, gastrointestinal, hepatic (e.g., ALAT   1  2.5 times the normal reference 
range) or hematological disease, and treatment with thiazolidinediones within the past 
3 months.
    The primary endpoint of the study was the change in the daily insulin dose (basal and 
prandial) after 6 months of treatment with either PIO or PLA given in addition to insulin. 
The total daily insulin dose was defined as the mean out of the daily insulin dose on 3 con-
secutive days before the respective visits. Secondary efficacy endpoints were the number of 
patients with a reduction of the daily insulin dose of   6  30%, various laboratory parameters 
such as HbA1c, glucose, C-peptide, intact proinsulin, adiponectin, relaxin, fetuin A, car-
bonyl protein, angiotensin, high-sensitivity C-reactive protein (hs-CRP), calcification mark-
ers (MPO, matrix Gla protein), lipids (cholesterol, HDL, LDL, triglycerides), matrix metal-
lopeptidase 9 (MMP-9), monocyte chemotactic protein-1 (MCP-1), soluble E-selectin, oxi-
dized LDL (ox LDL), PIO in serum, intact parathyroid hormone (PTH), and N-terminal 
fragment of pro-brain natriuretic peptide (NT -proBNP ). Laboratory efficacy parameters 
were measured using blood collected prior to dialysis at visit 2 (baseline), visit 5 (12 weeks 
later), and visit 7 (6 months later). The influence of the treatment on cardiac function was 
furthermore evaluated as the change in the ultrafiltrate volumes during the course of the 
study. Another objective was the safety surveillance including assessment of adverse events 
(AE) and safety laboratory parameters.
    After written informed consent was obtained from each participant, patients were ran-
domized to either receive an additional treatment with PIO (1   !   30 mg/day at breakfast) or 
PLA for 6 months. As depicted in  figure 1 , the trial consisted of a screening visit (Visit 1, V1), 
a randomization visit (baseline, V2), four treatment visits (V3–V6), and a final visit after 
6 months of treatment (V7). Advice for insulin dosage adaptation and choice of insulin was 
at the discretion of the investigator. At the discretion of the investigator, the initial insulin 
dose was reduced by 10% at the randomization visit (V2). Insulin was titrated to target a fast-
ing blood glucose level of 80–120 mg/dl.
    Patients were allowed to use any further concomitant medications that they required as 
far as they did not belong to those representing exclusion criteria. If medically acceptable, all 
concomitant medications had to be kept constant during the investigation.
  Laboratory  Methods 
 Glucose, creatinine, and lipids were determined by standard reference methods (COABS, 
Roche Diagnostics, Mannheim, Germany). Insulin and C-peptide were measured with che-
miluminescence (Liaison, Byk-Sangtec, Neu-Isenburg, Germany). ELISA methods were 
used to assess MPO, matrix Gla protein, relaxin (all Immundiagnostik AG, Bensheim, Ger-
many), intact proinsulin (TecoMedical, Sissach, Switzerland), angiotensin, NT-ProBNP, 107
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isoPGFa, MMP-9, MCP-1, and soluble E-selectin (all R&D Systems, Hamburg, Germany). 
hs-CRP was assessed by turbidimetry (Falcor, Menarini, Neuss, Germany).
  Statistical  Analysis 
 The power calculation was based on the assumption that the required insulin dose would 
vary by 20% and the assumption that a decrease by 30% would be considered clinically rel-
evant. Based on these conditions, the number per group required to have an 80% power (a = 
0.05) for denying the appropriate null-hypothesis was 10 patients per group. As there was a 
high number of dropouts expected over the 6-month treatment period, the planned number 
of patients was 20 per treatment arm. 
  The primary efficacy variable was analyzed by descriptive statistics (mean, standard de-
viation, minimum value, 1st quartile, median, 3rd quartile, maximum value) and inferential 
statistics [analysis of covariates (ANCOVA), Student’s t test, Wilcoxon rank test, confidence 
intervals within treatment group and between treatment groups]. Secondary efficacy param-
eters were analyzed by the same descriptive statistics, by confidence intervals and two-sided 
Student’s t tests.
  The following analysis set was used: (1) intention-to-treat (ITT) set: all patients who had 
been randomized; (2) full analysis set (FAS): all randomized patients who received study 
medication and who provided one post-baseline value for the daily insulin dose. Primary 
and secondary efficacy variables were analyzed for the FAS. Demographic data are displayed 
for the FAS as well. The ITT set was used for evaluation of medical history, physical exami-
nation, concurrent diseases, concomitant medications, and safety issues (AEs, laboratory 
safety parameters). The analyses were performed by means of the SPSS software (version 
16.0, SPSS Inc., Chicago, Ill., USA). A p value   !  0.05 was considered to be of statistical sig-
nificance.
  R e s u l t s  
  The study was performed between August 2008 and June 2009. Screening of 52 patients 
in 14 study centers led to an ITT set of 39 patients aged between 50 and 80 years (69% male). 
Three patients were erroneously randomized and therefore excluded prior to visit 3 as they 
did not meet all inclusion criteria. Therefore, the FAS consisted of 36 patients. Due to drop-
outs, the per protocol set (PPS) finally consisted of 26 patients, 15 belonging to the PIO group 
and 11 to the PLA group. Details about the reasons for dropout can be found in   figure 2  .
  Fig. 1.   Overview of the study de-
sign with two treatment arms. 
The chronological order of visits 
and their temporal spreading are 
depicted. 108
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    Demographics and Baseline Characteristics  
 The most relevant demographic and baseline characteristics of patients belonging to the 
ITT set are summarized in   table 1  . These characteristics are corresponding for patients of 
both treatment groups. Consequently, the composition of both treatment groups represents 
a sound basis for a meaningful evaluation of the obtained data.
  Efficacy  Endpoints 
  Efficacy variables were analyzed for the FAS. The primary efficacy variable was the 
change of the total daily insulin dose after 6 months of treatment (V7) as compared to the 
baseline visit (V2). The mean daily insulin dosage at baseline was larger in the PIO group as 
compared to the PLA group. In the PIO group, mean daily insulin dose was reduced by 35% 
(from 63.96   8   48.90 to 41.72   8   33.97 IU), while a decrease by 10% could be seen in the PLA 
arm (from 55.37   8   32.96 to 49.95   8   29.33 IU;   table 2  ). Non-parametric Wilcoxon rank test 
indicated that the reduction in the total daily insulin requirements for the PIO group versus 
the PLA group was statistically     significant (p = 0.003).
  Fig. 2.  Flowchart with numbers of patients that were screened, randomized, and assigned to the two treat-
ment arms and treated accordingly (FAS) without major protocol violation as stipulated by the protocol 
(PPS). 109
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  An insulin reduction of  6 30% was defined as a positive response to treatment and eval-
uated as a secondary efficacy variable. As depicted in   table 2  , 8 patients (out of 18, 44%) in 
the PIO group and 1 patient (out of 13, 8%) in the PLA group reached such a decrease in the 
daily insulin dose after 6 months. Comparison of HbA1c values at baseline and after 
6 months demonstrates a statistically significant decrease of 8.08% in the PIO group (p = 
0.015), whereas in the PLA group the values increased by 2.68% (n.s.). Comparison between 
treatment groups indicates that the change in the PIO versus the PLA group is statistically 
significant with a p value of 0.004 (  table 2  ). PIO treatment resulted in a reduction of the fast-
ing blood glucose levels most pronounced at 6 months (–24.24%) in comparison to baseline. 
Contrarily, blood glucose levels in the PLA group increased (9.9%) at 6 months versus base-
line (  table 2  ). However, between-treatment-group confidence intervals and Student’s t tests 
demonstrate that this reduction in blood glucose is not statistically significant.
  As for control of the cardiovascular risk profile several parameters concerning lipid me-
tabolism and inflammation were analyzed. Changes of these secondary efficacy parameters 
after 6 months versus baseline are displayed in   table 3  .
  PIO administration resulted in a pronounced decrease of the level of triglycerides (–30%), 
while an increase was observed for the PLA group (19%). HDL levels increased slightly in the 
PIO group (5%), whereas they declined in the PLA group (–23%). Total cholesterol levels de-
creased in both treatment groups (PIO –7%, PLA –21%). LDL values were only reduced in 
Table 1.   Demographic and baseline characteristics of patients of both treatment groups for the ITT set 
(except for ultrafiltrate volumes, which are given for the FAS)
PIO PLA
Patients 20 19
Male/female 14/6 13/6
Age, years 68.986.8 69.689.4
Diabetes duration, years 13.889.8 12.488.2
BMI 31.584.0 30.384.6
Systolic blood pressure, mm Hg 143.4819.5 144.6822.8
Diastolic blood pressure, mm Hg 72.7813.3 73.2812.3
Ultrafiltrate volume, ml per dialysis session 2,5048855 2,7438999
D  ata are numbers or mean 8 SD. 
Table 2.   Observation parameters at baseline and endpoint at 6 months
PIO P LA
baseline 6 months baseline  6 months
Daily insulin dose, IU 63.96848.90 41.72833.97* 55.37832.96 49.95829.33*
Daily insulin dose reduction >30%, n 0 8 0 1
HbA1c, %
Mean change vs. baseline 8 SD
7.480.9 6.881.0*
–0.6080.87
7.780.9 7.981.0*
0.2181.10
Glucose, mg/dl
Mean change vs. baseline 8 SD
152.5845.0 115.5844.3
–36.96870.53
156.6843.6 172.1881.7
15.51868.61
* p   < 0.05 comparison of PIO vs. PLA at 6 months.110
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the PLA group (–33%), whereas they were increased in the PIO group (4%). Finally, adipo-
nectin levels were increased by PIO (80%), and decreased by PLA (–14%). However, among 
all the differences described only the change in adiponectin levels reached statistical signif-
icance for between- (p = 0.001) and in-group comparison (p   !   0.001).
    Concerning parameters used for evaluation of arterial inflammation, the level of the 
  endothelial inflammation marker E-selectin was reduced by PIO administration (–16%), 
whereas it was increased in the PLA group (15%). The change was statistically significant for 
within- (p = 0.029) and between-group comparison (p = 0.014). MCP-1 levels were almost 
unchanged upon PIO administration, but considerably increased in the PLA group. As for 
MMP-9 levels, no clear trend is obvious for either treatment group. No treatment-emergent 
effect of PIO was observed in the level of hs-CRP. The level of ox LDL was strongly increased 
in the PIO group and reduced in the PLA group. Carbonyl protein levels were increased in 
the PIO group, while in the PLA group, they were almost unchanged. Levels of fetuin A and 
relaxin showed the same tendencies to a slight reduction in both treatment groups. Un-
changed or slightly reduced levels in both treatment groups were observed for the matrix Gla 
protein. For intact parathyroid hormone, a trend towards a decreased level in the PIO group 
and an increase in the PLA group was observed. 
    Of the cardiac risk markers analyzed, levels of myeloperoxidase increased in the PIO 
group during the study at V5 but were reduced compared to baseline after 6 months of treat-
ment. In the PLA group, myeloperoxidase levels increased. NT-proBNP showed a trend to-
wards a higher level in the PLA group in comparison to the PIO group, but levels fluctuated 
very strongly during the study. However, the differences mentioned above did not reach sta-
tistical significance.
  While ultrafiltrate volumes of the PIO group fluctuated in the range of 2,504 ml at base-
line and 2,618 ml at 6 months, those of the PLA group varied from 2,743 ml at baseline to 
Table 3.   Changes of the secondary efficacy parameters between endpoint at 6 months and baseline
Secondary efficacy parameter C  hanges V7 (endpoint) vs. V2 (baseline)
PIO PLA
n mean 8 SD (median) change, % n mean 8 SD (median) change, %
Adiponectin, g/ml 18 7.3384.80 (8.06) 79.62 13 –1.3782.56 (–1.09) –14.02
Fetuin A, g/l 18 –0.0480.12 (–0.02) –6.88 13 –0.0980.20 (–0.03) –14.62
hs-CRP, mg/l 13 0.6381.54 (0.91) 20.08 7 0.4980.70 (1.17) 12.66
Cholesterol, mg/dl 13 –14.86847.90 (14.50) –7.25 7 –40.61871.87 (–24.00) –20.7
HDL, mg/dl 13 1.4786.07 (1.00) 4.72 7 –7.8188.58 (–3.00) –22.9
LDL, mg/dl 13 4.21838.32 (15.50) 4.35 7 –35.14846.68 (–32.00) –32.54
Triglycerides, mg/dl 13 –107.758140.21 (–101.00) –30.24 7 45.388110.95 (1.00) 19.15
MMP-9, ng/ml 18 89.148548.68 (–26.69) 13.13 13 193.848594.80 (237.28) 23.79
MCP-1, pg/ml 18 –9.588129.09 (–5.08) –1.69 13 300.08978.58 (52.10) 46.83
E-selectin, ng/ml 18 –7.4813.93 (–7.98) –16.27 13 6.81813.73 (6.43) 14.73
Intact parathyroid hormone, ng/l 18 –87.358420.64 (–12.00) –26.9 13 85.618142.99 (90.00) 31.3
NT-proBNP, pg/ml 18 2,952.18815,223.51 (–350.00) 57.5 13 5,273.61814,495.30 (996.00) 104.38
Ultrafiltrate volume, ml 18 113.488617.00 (202.45) 4.53 14 361.718567.72 (483.30) 13.19
Relaxin, pg/ml 18 –4.11837.54 (–1.60) –16.95 13 –5.70831.93 (–6.86) –21.14
Carbonyl protein, nmol/ml 18 2.7787.31 (1.47) 24.3 13 0.4686.66 (0.82) 2.97
Angiotensin, pmol/l 18 –4.41834.49 (3.52) –17.25 13 5.02843.34 (–1.98) 21.49
Myeloperoxidase, ng/ml 18 –15.248111.78 (–2.13) –20.28 13 8.05836.43 (8.00) 17.97
Matrix Gla protein, nmol/l 18 0.1284.19 (2.59) 0.83 13 –1.4085.34 (–0.32) –9.44
ox LDL, ng/ml 13 41.08823.29 (0) 69.64 7 –17.98823.39 (0) –26.4
Th  e number of patients (n) as well as absolute (mean 8 SD, median) and percentage changes are depicted for the FAS of both treatment 
groups.111
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3,105 ml at 6 months. The ultrafiltrate volumes in the PLA group increased by 13.19% com-
pared to 4.53% in the PIO group. The difference, however, was not statistically significant.
  No statistically significant effects of PIO treatment on vital signs (weight, BMI, waist and 
hip circumference, blood pressure, and pulse) were observed in this study.
  S a f e t y   A n a l y s i s  
  The ITT set was used to address safety issues. In total, 129 AEs occurred in the ITT set 
of this clinical trial. A slightly higher number of AEs was reported for patients of the PLA 
group (n = 68) than for those of the PIO group (n = 61). As summarized in   table 4  , the ma-
jority of the AEs were gastrointestinal disorders, additional investigations, infectious disor-
ders, and musculosceletal and connective tissue disorders. Most AEs were classified as ‘mild’ 
(PIO: 60.7%; PLA: 60.3%) and ‘moderate’ (PIO: 37.7%; PLA: 32.4%). AEs graded as ‘severe’ 
were observed once in the PIO group and 5 times in the PLA group.
  The vast majority of AEs (n = 109; 84.5%) was classified as unlikely or not related to treat-
ment (PIO: n = 51; PLA: n = 58). Only 1 moderate AE in the PLA group was judged to be 
definitely related to treatment. Eight AEs (PIO: n = 3; PLA: n = 5) were assessed as probably 
caused by treatment.
  A major focus of the safety evaluation was the occurrence of hypoglycemic episodes un-
der combination treatment of PIO with insulin. There were 5 cases of hypoglycemia (all mild 
in nature) reported from 2 patients in the PIO group, and in the PLA group 2 patients suf-
fered from 3 cases of hypoglycemia (1 mild and 2 moderate).
  Discussion 
  The aim of the present study was to compare the effect of PIO versus PLA when admin-
istered in addition to insulin in patients with type 2 diabetes mellitus and renal failure re-
quiring hemodialysis. For this purpose, 39 patients were randomized to the two treatment 
Table 4.   Number of AEs in both treatment groups and their intensity, classified and sorted according to system organ class 
(SOC) for the ITT set
S  OC Total PIO PLA 
intensity of AE total intensity of AE total 
mild mod. sev. NA mild mod. sev. NA
Gastrointestinal disorders 20 6 1 0 0 7 10 3 0 0 13
Investigations 18 7 2 0 0 9 3 5 1 0 9
Infections and infestations 17 4 4 0 0 8 6 3 0 0 9
Musculoskeletal and connective tissue disorders 17 5 3 0 0 8 5 3 1 0 9
Injury, poisoning and procedural complications 14 3 5 0 0 8 3 2 1 0 6
Metabolism and nutrition disorders 11 5 0 0 0 5 4 2 0 0 6
Vascular disorders 9 1 4 1 0 6 0 2 1 0 3
Cardiac disorders 7 1 1 0 0 2 3 2 0 0 5
Nervous system disorders 4 2 0 0 0 2 2 0 0 0 2
Skin and subcutaneous tissue disorders 4 2 0 0 0 2 2 0 0 0 2
General disorders and administration site conditions 3 0 0 0 0 0 2 0 1 0 3
Eye disorders 2 0 2 0 0 2 0 0 0 0 0
Surgical and medical procedures 2 0 1 0 0 1 1 0 0 0 1
Blood and lymphatic system disorders 1 1 0 0 0 1 0 0 0 0 0
Total 129 37 23 1 0 61 41 22 5 0 68
mod.   = Moderate; sev. = severe; NA = not available.112
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arms. One patient of the PIO group and 2 patients of the PLA group were early dropouts. 
Therefore, the FAS was made up of 19 and 17 patients treated with either PIO or PLA, respec-
tively  ( fig. 1 ).
    Evaluation of the primary efficacy variable after 6 months of treatment indicates a ben-
eficial effect of PIO administration on insulin requirements (  table 2  ). The low number of 
patients and the resultant fluctuation of the values impaired statistical confirmation of this 
result. Therefore, parametric ANCOVA and Student’s t test could not be reliably applied be-
cause of violations of normal distribution and variance of the values. Use of the non-para-
metric Wilcoxon rank test revealed that PIO intake resulted in a statistically significant re-
duction of insulin requirements in patients with type 2 diabetes mellitus and renal failure as 
compared to patients receiving PLA.
    The reduced insulin requirement went in parallel with an improvement in the second-
ary efficacy parameters regarding glycemic control (  table 2  ). A statistically significant high-
er number of patients of the PIO group reached a   1  30% reduction of the daily insulin dose 
after 6 months of treatment. The HbA1c value showed a statistically significant reduction in 
the PIO group, while it remained almost constant in the PLA group.
    Lipids were differently affected by the two treatments (  table 3  ). In contrast to PLA, PIO 
administration resulted in a beneficial effect regarding triglyceride and HDL levels. Total 
cholesterol levels were decreased in both treatment groups, whereas LDL levels were only re-
duced in the PLA group. Adiponectin levels were increased statistically significant in the PIO 
group, whereas they decreased in the PLA group. An increase of adiponectin upon PIO ad-
ministration was previously reported and may be related to improved insulin resistance  [20] . 
Reduced levels of triglycerides as well as slightly higher HDL levels may indicate a potential 
beneficial effect of PIO on atherosclerotic events. With respect to these positive effects, the 
statistically significant reduced level of the endothelial inflammation marker E-selectin in 
the PIO group is noteworthy (  table 3  ). In line with these findings is the reduced amount of 
MCP-1 in the PIO group (  table 3  ). These beneficial effects of PIO on E-selectin and MCP-1 
were previously described for type 2 diabetes mellitus patients without renal failure, too  [21] . 
Among the other atherosclerotic risk markers analyzed, hs-CRP and ox LDL have to be 
pointed out. No treatment-emergent effect of PIO was observed on the level of hs-CRP (  ta-
ble 3  ), deviating from the usually found decrease of hs-CRP due to PIO application in type 
2 diabetes mellitus patients with normal renal function  [13, 20] . The level of ox LDL, a mark-
er for oxidative stress, was strongly increased in the PIO group (  table 3  ).
  The effect of PIO administration on levels of myeloperoxidase was ambiguously showing 
an increase during the study, but a reduction after 6 months of treatment (  table 3  ). Although 
the levels of NT-proBNP fluctuated very strongly, a trend towards a lower level in the PIO 
group was observable (  table 3  ). Average values of ultrafiltrate volumes of 6 consecutive di-
alyses prior to individual visits were calculated and increases   1  30% in comparison to base-
line were considered as worsening of heart insufficiency. Five patients (PIO: n = 2; PLA: n = 
3) of the FAS exhibited a stronger increase and therefore had to discontinue study participa-
tion. The vast majority did not show a pronounced increase in the ultrafiltrate volume and, 
thus, was apparently not affected by worsening of heart insufficiency. Generally, ultrafiltrate 
volumes increased slightly stronger in the PLA group versus the PIO group during the course 
of the study (  table 3  ). These findings indicate the absence of an adverse effect of PIO admin-
istration on heart function in patients of this study.
    To date, only few reports exist in the literature about the effects of PIO in hemodialysis 
patients with type 2 diabetes mellitus. In general, they show that PIO is effective in glycemic 
control and well tolerated in that particular patient group   [22–24]  . However, these reports 
are well in line with the results of the present trial. In conclusion, this prospective, random-
ized, parallel, double-blind, PLA-controlled multi-center phase II trial showed that addition 113
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of PIO to insulin is well tolerated in patients with type 2 diabetes mellitus requiring hemo-
dialysis. No indications for a volume overload accompanied by symptoms of heart failure and 
no indications for a hypoglycemia risk were found with this treatment. In fact, addition of 
PIO showed an improved glycemic control with a simultaneous significant reduction in dai-
ly insulin requirements.
  Conclusion 
  Addition of PIO to insulin in patients with type 2 diabetes requiring hemodialysis re-
sulted in a decrease of the daily insulin dose and an improved glycemic control. Further-
more, PIO administration was well tolerated without any indications of volume overload and 
negative influence on hypoglycemia risk.
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